199 related articles for article (PubMed ID: 30791788)
1. Adverse events in IBD therapy: the 2018 update.
Quezada SM; McLean LP; Cross RK
Expert Rev Gastroenterol Hepatol; 2018 Dec; 12(12):1183-1191. PubMed ID: 30791788
[TBL] [Abstract][Full Text] [Related]
2. The risk for opportunistic infections in inflammatory bowel disease with biologics: an update.
Borman ZA; Côté-Daigneault J; Colombel JF
Expert Rev Gastroenterol Hepatol; 2018 Nov; 12(11):1101-1108. PubMed ID: 30277409
[TBL] [Abstract][Full Text] [Related]
3. Evolving Considerations for Thiopurine Therapy for Inflammatory Bowel Diseases-A Clinical Practice Update: Commentary.
Hanauer SB; Sandborn WJ; Lichtenstein GR
Gastroenterology; 2019 Jan; 156(1):36-42. PubMed ID: 30195449
[TBL] [Abstract][Full Text] [Related]
4. Biological therapy in pediatric age.
Penagini F; Cococcioni L; Pozzi E; Dilillo D; Rendo G; Mantegazza C; Zuccotti GV
Pharmacol Res; 2020 Nov; 161():105120. PubMed ID: 32783974
[TBL] [Abstract][Full Text] [Related]
5. Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia.
Ooi CJ; Hilmi I; Banerjee R; Chuah SW; Ng SC; Wei SC; Makharia GK; Pisespongsa P; Chen MH; Ran ZH; Ye BD; Park DI; Ling KL; Ong D; Ahuja V; Goh KL; Sollano J; Lim WC; Leung WK; Ali RAR; Wu DC; Ong E; Mustaffa N; Limsrivilai J; Hisamatsu T; Yang SK; Ouyang Q; Geary R; De Silva JH; Rerknimitr R; Simadibrata M; Abdullah M; Leong RWL;
J Gastroenterol Hepatol; 2019 Aug; 34(8):1296-1315. PubMed ID: 30848854
[TBL] [Abstract][Full Text] [Related]
6. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
Nørgård BM
Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
[TBL] [Abstract][Full Text] [Related]
7. Adverse events in IBD: to stop or continue immune suppressant and biologic treatment.
McLean LP; Cross RK
Expert Rev Gastroenterol Hepatol; 2014 Mar; 8(3):223-40. PubMed ID: 24490595
[TBL] [Abstract][Full Text] [Related]
8. Short article: Switching to a infliximab biosimilar: short-term results of clinical monitoring in patients with inflammatory bowel disease.
Binkhorst L; Sobels A; Stuyt R; Westerman EM; West RL
Eur J Gastroenterol Hepatol; 2018 Jul; 30(7):699-703. PubMed ID: 29538037
[TBL] [Abstract][Full Text] [Related]
9. Methotrexate for inflammatory bowel disease: time for reconsideration.
Nielsen OH; Ainsworth MA; Steenholdt C
Expert Rev Gastroenterol Hepatol; 2019 May; 13(5):407-409. PubMed ID: 30895827
[No Abstract] [Full Text] [Related]
10. Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease.
Renna S; Cottone M; Orlando A
World J Gastroenterol; 2014 Aug; 20(29):9675-90. PubMed ID: 25110407
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Clinical Outcomes After Switching from Remicade
Smits LJT; Grelack A; Derikx LAAP; de Jong DJ; van Esch AAJ; Boshuizen RS; Drenth JPH; Hoentjen F
Dig Dis Sci; 2017 Nov; 62(11):3117-3122. PubMed ID: 28667429
[TBL] [Abstract][Full Text] [Related]
12. Systematic Review of Effects of Withdrawal of Immunomodulators or Biologic Agents From Patients With Inflammatory Bowel Disease.
Torres J; Boyapati RK; Kennedy NA; Louis E; Colombel JF; Satsangi J
Gastroenterology; 2015 Dec; 149(7):1716-30. PubMed ID: 26381892
[TBL] [Abstract][Full Text] [Related]
13. Biosimilars in Inflammatory Bowel Disease - Accumulating Clinical Evidence.
McConachie S; Wilhelm SM; Kale-Pradhan PB
Expert Rev Clin Pharmacol; 2017 Apr; 10(4):391-400. PubMed ID: 28095262
[TBL] [Abstract][Full Text] [Related]
14. Insights in immunomodulatory therapies for ulcerative colitis and Crohn's disease.
Nguyen GC; Harris ML; Dassopoulos T
Curr Gastroenterol Rep; 2006 Dec; 8(6):499-505. PubMed ID: 17105689
[TBL] [Abstract][Full Text] [Related]
15. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea.
Park SH; Kim YH; Lee JH; Kwon HJ; Lee SH; Park DI; Kim HK; Cheon JH; Im JP; Kim YS; Lee SY; Lee SJ
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():35-44. PubMed ID: 26395533
[TBL] [Abstract][Full Text] [Related]
16. Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease.
Hyams JS; Dubinsky MC; Baldassano RN; Colletti RB; Cucchiara S; Escher J; Faubion W; Fell J; Gold BD; Griffiths A; Koletzko S; Kugathasan S; Markowitz J; Ruemmele FM; Veereman G; Winter H; Masel N; Shin CR; Tang KL; Thayu M
Gastroenterology; 2017 Jun; 152(8):1901-1914.e3. PubMed ID: 28193515
[TBL] [Abstract][Full Text] [Related]
17. Safety of anti-tumor necrosis factor therapy during pregnancy in patients with inflammatory bowel disease.
Androulakis I; Zavos C; Christopoulos P; Mastorakos G; Gazouli M
World J Gastroenterol; 2015 Dec; 21(47):13205-11. PubMed ID: 26715803
[TBL] [Abstract][Full Text] [Related]
18. Psoriasiform Skin Lesions Are Caused by Anti-TNF Agents Used for the Treatment of Inflammatory Bowel Disease.
George LA; Gadani A; Cross RK; Jambaulikar G; Ghazi LJ
Dig Dis Sci; 2015 Nov; 60(11):3424-30. PubMed ID: 26115749
[TBL] [Abstract][Full Text] [Related]
19. Preventing infective complications in inflammatory bowel disease.
Mill J; Lawrance IC
World J Gastroenterol; 2014 Aug; 20(29):9691-8. PubMed ID: 25110408
[TBL] [Abstract][Full Text] [Related]
20. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study.
Jahnsen J; Detlie TE; Vatn S; Ricanek P
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():45-52. PubMed ID: 26395534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
